Given that angiogenesis is essential for O2 supply and nutrition during tumor growth [3, 4], we utilized anti-angiogenic therapy with bevacizumab, an anti-VEGF antibody used for GBM, to enhance hypoxia in GBM xenografts. The gene discussed is VEGFA; the disease is glioblastoma.